Recruiting Ovarian Cancer Studies in Rochester
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of...
Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopian tube or primary peritoneal cancer. FRα...
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
This is an open-label, phase 1/2, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pe...
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed,...
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patie...
About Ovarian Cancer Clinical Trials in Rochester
Ovarian cancer originates in the ovaries or fallopian tubes and is often called a "silent killer" due to subtle early symptoms. It is the fifth leading cause of cancer death among women. Treatment typically involves surgery and chemotherapy, with newer targeted therapies showing promise.
There are currently 5 ovarian cancer clinical trials recruiting participants in Rochester, NY. These studies are seeking a combined 1,154 participants. Research is being sponsored by Regeneron Pharmaceuticals, Mayo Clinic, TILT Biotherapeutics Ltd. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ovarian Cancer Clinical Trials in Rochester — FAQ
Are there ovarian cancer clinical trials in Rochester?
Yes, there are 5 ovarian cancer clinical trials currently recruiting in Rochester, NY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Rochester?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rochester research site will contact you about next steps.
Are clinical trials in Rochester free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rochester studies also compensate for your time and travel.
What ovarian cancer treatments are being tested?
The 5 active trials in Rochester are testing new therapies including novel drugs, biologics, and treatment approaches for ovarian cancer.
Data updated March 2, 2026 from ClinicalTrials.gov